Study to Evaluate the Efficacy and Safety of CUDC-907 in Patients With RR DLBCL, Including Patients With MYC Alterations
Status:
Completed
Trial end date:
2019-07-26
Target enrollment:
Participant gender:
Summary
This is a Phase 2, open-label, multicenter trial designed to evaluate the efficacy and safety
of CUDC-907 in subjects 18 years and older with Relapsed/Refractory (RR) MYC-altered Diffuse
Large B-Cell Lymphoma (DLBCL).